Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines

被引:85
作者
Gabizon, A
Chemla, M
Tzemach, D
Horowitz, AT
Goren, D
机构
[1] Sharet Institute of Oncology, Hadassah Hebrew Univ. Medical Center
关键词
liposomes; anthracyclines; pharmacokinetics; chemotherapy; animal tumors;
D O I
10.3109/10611869608996830
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of liposome composition on drug delivery to tumors and therapeutic efficacy of liposome-encapsulated anthracyclines was investigated in two murine tumor models: an ascitic tumor (J6456 lymphoma) and a solid carcinoma (M-109). Longevity in circulation correlated positively with high drug levels in the extracellular (ascitic) tumor fluid and with delayed peak tumor levels. Using polyethylene-glycol(PEG)-coated liposomes, liposome stability (drug retention) was found to be an important determinant of therapeutic efficacy, as indicated by the superior survival conferred by high T-m phosphatidylcholines (hydrogenated, dipalmitoyl) over low T-m (egg phosphatidyl-choline). Replacing PEG with another negatively-charged surface headgroup (phosphatidyl-glycerol, phosphatidyl-inositol) resulted in relatively shorter longevity in circulation of the liposome-associated drug, but no detectable differences in anti-tumor efficacy. When neither the surface charged headgroup nor the PEG coating are present, the resulting drug formulation was significantly less effective than PEG and phosphatidylinositol-based formulations in both tumor models. In conclusion, longevity in circulation, as obtained with PEG coating, tends to improve the therapeutic efficacy of liposome-encapsulated anthracyclines. The current therapeutic models were however unable to detect differences between the therapeutic activity of PEG and other liposome formulations with relatively small differences in circulation longevity.
引用
收藏
页码:391 / 398
页数:8
相关论文
共 26 条
  • [1] COWENS JW, 1993, CANCER RES, V53, P2796
  • [2] FORSSEN EA, 1992, CANCER RES, V52, P3255
  • [3] ENHANCEMENT OF GROWTH OF A RADIATION-INDUCED LYMPHOMA BY T-CELLS FROM NORMAL MICE
    GABIZON, A
    TRAININ, N
    [J]. BRITISH JOURNAL OF CANCER, 1980, 42 (04) : 551 - 558
  • [4] GABIZON A, 1990, CANCER RES, V50, P6371
  • [5] GABIZON A, 1982, CANCER RES, V42, P4734
  • [6] LIPOSOME FORMULATIONS WITH PROLONGED CIRCULATION TIME IN BLOOD AND ENHANCED UPTAKE BY TUMORS
    GABIZON, A
    PAPAHADJOPOULOS, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (18) : 6949 - 6953
  • [7] PROLONGATION OF THE CIRCULATION TIME OF DOXORUBICIN ENCAPSULATED IN LIPOSOMES CONTAINING A POLYETHYLENE GLYCOL-DERIVATIZED PHOSPHOLIPID - PHARMACOKINETIC STUDIES IN RODENTS AND DOGS
    GABIZON, AA
    BARENHOLZ, Y
    BIALER, M
    [J]. PHARMACEUTICAL RESEARCH, 1993, 10 (05) : 703 - 708
  • [8] GABIZON AA, 1994, HEMATOL ONCOL CLIN N, V8, P431
  • [9] GABIZON AA, 1992, CANCER RES, V52, P891
  • [10] PHASE I/II CLINICAL AND PHARMACOKINETIC EVALUATION OF LIPOSOMAL DAUNORUBICIN
    GILL, PS
    ESPINA, BM
    MUGGIA, F
    CABRIALES, S
    TULPULE, A
    ESPLIN, JA
    LIEBMAN, HA
    FORSSEN, E
    ROSS, ME
    LEVINE, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) : 996 - 1003